Publications by authors named "T S Jokiranta"
Objectives: With the global spread of antimicrobial resistance, treating urinary tract infections (UTIs) is becoming more challenging. Clinical data on UTI outcomes are scarce in cases with antimicrobial treatment mismatching the uropathogens' susceptibility profiles. We explored the association of (mis)matching antimicrobial treatment and clinical outcomes among patients with either ESBL-producing Enterobacterales (ESBL-PE) or non-ESBL-PE identified in urine samples.
View Article and Find Full Text PDFBackground: No licensed human vaccines are available against enterotoxigenic Escherichia coli (ETEC), a major diarrhoeal pathogen affecting children in low- and middle-income countries and foreign travellers alike. ETVAX®, a multivalent oral whole-cell vaccine containing four inactivated ETEC strains and the heat-labile enterotoxin B subunit (LTB), has proved promising in Phase 1 and Phase 1/ 2 studies.
Methods: We conducted a Phase 2b double-blinded, randomized, placebo-controlled trial amongst Finnish travellers to Benin, West Africa.
Article Synopsis
- The study investigates the reasons for treatment interruptions in patients using TNF-inhibitors (infliximab and adalimumab) and how these interruptions impact immunisation and treatment switching.
- Based on a survey of 370 patients from various hospitals in Finland, it was found that treatment interruptions were significantly linked to immunisation and more common among those treated for rheumatic diseases.
- The most frequent interruption cause was infections, and such interruptions can lead to increased immunisation risk and a greater need for switching medications, highlighting the need for careful clinical decision-making.
Article Synopsis
- * It was found that immunization (anti-drug antibodies, or ADAb) affected drug efficacy, with 11% of patients having detectable ADAb, most notably in those using certolizumab pegol.
- * Methotrexate use was shown to reduce the risk of ADAb formation, while low drug trough levels were common and linked to higher disease activity, highlighting the importance of monitoring drug levels in treated patients.
Objectives: We set out to determine the reasons for serum vedolizumab (VDZ) trough concentration (TC) measurements in inflammatory bowel disease (IBD) patients and to evaluate treatment modifications after therapeutic drug measurement (TDM). We also evaluated the effect of increased dosing on patients' response to VDZ therapy.
Methods: We performed a retrospective cohort study of IBD patients who received VDZ therapy at Helsinki University Hospital and whose VDZ levels were measured between June 2014 and December 2018.